Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab for LGI1 autoimmune encephalitis
NL-OMON54436Phase 2Completed
- Sponsor
- UCB
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Encephalitis (AE) and Anti-leucine-rich glioma inactivated 1 encephalitis comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Sustained seizure freedom through Week 25. Started Apr 2023; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
Autoimmune Encephalitis (AE)Anti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on NL-OMON54436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54436.